Stifel raised the firm’s price target on Ligand (LGND) to $230 from $220 and keeps a Buy rating on the shares after an investor day that the firm says covered “key growth drivers within its diverse royalty portfolio as well as recent value-creating transactions” that will support achieving the raised five-year royalty compound annual growth rate of greater than 23%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND: